Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
This facility manufactures APIs & formulations of oncology and non-oncology products.
Sun Pharma's Dadra facility receives OAI status from US FDA
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Total value of the supplies of FC will be US$ 2.773 million
Subscribe To Our Newsletter & Stay Updated